News
Stay Ahead with the Latest Industry Trends & Market Insights with Industry News đź“°

Post-Traumatic Stress Disorder Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: August 2024 || SKU: PH1485
excelpdfpowerpoint
180 pages
Report Summary
Table of Contents
List of Tables & Figures
Get Free Sample

See how US Tariffs impact Post-Traumatic Stress Disorder Therapeutics Market

Don’t get cau

Global Post-Traumatic Stress Disorder Therapeutics Market is segmented By Product Type (Antidepressants, Anti-anxiety Drugs, Antipsychotics, Others), By Age Group (Adults, Children), By Route of Administration (Oral, Parenteral, Transdermal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

 

Report Overview

The Global Post-Traumatic Stress Disorder Therapeutics Market reached US$ 2.36 billion in 2023 and is expected to reach US$ 3.96 billion by 2031, growing at a CAGR of 6.9% during the forecast period 2024-2031.

Posttraumatic stress disorder (PTSD) is a psychological disorder that affects people who have encountered or seen traumatic events, occurrences, or conditions. It may be both emotionally and physically destructive, impacting one's mental, physical, social, and spiritual health. Natural catastrophes, accidents, terrorism, war, rape, historical trauma, intimate relationship abuse, and bullying are among examples.

 

Market Scope

Metrics

Details

CAGR

XX%

Market Size Available for Years

2022-2031

Estimation Forecast Period

2024-2031

Revenue Units

Value (US$ Mn) 

Segments Covered

Drug Type, Age Group, Route of Administration, End User

Regions Covered

North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Largest Region

North America

Fastest Growing Region

Asia-Pacific

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.

 

For More Insights Download Sample

 

Market Dynamics: Drivers & Restraints

Drivers

Rise in the prevalence of post-traumatic stress disorders

Post-traumatic stress disorder (PTSD) is a global health concern, arising from exposure to traumatic events like military combat, natural disasters, accidents, or personal assaults. The increasing prevalence of PTSD, especially among military personnel, first responders, and victims of violence or disasters, is boosting demand for effective treatments and improved diagnosis. For instance, It affects 3.5% of U.S. adults annually, with an estimated one in 11 diagnosed in their lifetime. Women are twice as likely as men to have PTSD.

Restraints

Side effects associated with the drugs

The global post-traumatic stress disorder treatment market faces a significant challenge due to the lack of awareness and understanding of side effects associated with drugs like Sertraline and Paroxetine. Sertraline has various side effects like syncope, lightheadedness, diarrhea, nausea, and more, while Paroxetine has side effects like mood changes, anxiety, serotonin syndrome, eye problems, allergic reactions, bruising, seizures, manic episodes, changes in appetite or weight, low sodium levels, and bone fractures.

Market Segment Analysis

The global post-traumatic stress disorder therapeutics market is segmented based on drug type, age group,  route of administration, end-user, and region.

The anti-depressants  from the drug type segment accounted for approximately 45.3 % of the post-traumatic stress disorder therapeutics  market share

The anti-depressants from the drug type segment accounted for approximately 45.3 %. SSRIs are commonly used antidepressants to treat depression and anxiety associated with PTSD. They increase serotonin levels in the brain, which regulates mood, appetite, and sleep, improving nerve cell communication, leading to improved mood and decreased anxiety. The industry is utilizing competitive strategies like mergers, acquisitions, distribution channel enhancement, product development, and research partnerships to develop effective antidepressant drugs and maintain competitiveness which overall help the segment growth during the forecast period.

Market Geographical Share

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like the novel product launches, FDA approvals, rising prevalence of the PTSD and increasing patient awareness about mental health and other factors help the region to grow during the forecast period.

For instance, in January 2024, Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has determined that the supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) is sufficiently complete to permit a substantive review. The FDA has assigned the application for a Prescription Drug User Fee Act (PDUFA) target action date of February 8, 2025.

Market Major Players

The major global players in the market include Pfizer Inc, Eli Lily and Company, GlaxoSmithKline Plc, H. Lundbeck, Otsuka Pharmaceutical Co., Ltd, Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc, Bionomics Ltd, Tonix, Pharmaceuticals Holding Corp, Apotex, Incamong others.

Key Developments

  • In April 2024, The University of the Sunshine Coast established the National PTSD Research Centre, a $18.5 million national hub, to address the mental health issue of PTSD, which affects nearly half of Australians directly or indirectly.

Why Purchase the Report?

  • To visualize the global post-traumatic stress disorder therapeutics market segmentation based on drug type, age group, route of administration, end-user, and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development. 
  • Excel data sheet with numerous data points of the post-traumatic stress disorder therapeutics market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global post-traumatic stress disorder therapeutics market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
Buy this report
Single User
$4350
Multiple User
$4850
Enterprise User
$7850
Proceed to Buy
  Get Free Sample
  Request new version
  Customize Sample
  Demo Full Report
Chat on WhatsApp
FAQ’s

  • Global Post-Traumatic Stress Disorder Therapeutics Market reached US$ 2.36 billion in 2023 and is expected to reach US$ 3.96 billion by 2031

  • Key players are Pfizer Inc, Eli Lily and Company, GlaxoSmithKline Plc, H. Lundbeck, Otsuka Pharmaceutical Co., Ltd, Novartis AG, AstraZeneca Plc, Azevan Pharmaceuticals, Inc, Bionomics Ltd, Tonix, Pharmaceuticals Holding Corp, Apotex, and Incamong.
Related Reports
pharmaceuticals-pa

Bipolar Disorder (Manic Depression) – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2022 August 11

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Breathing Disorder Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 November 06

Starting from

$4350

pharmaceuticals iconpharmaceuticals

Metabolic Disorders Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Published: 2024 December 27

Starting from

$4350

WhatsApp